CALU

Calumenin · O43852 · CALU on Sugi Atlas →

0 patent compounds predicted against CALU, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to CALU by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Dexmedetomidine and Total Intravenous Anesthesia on Endothelial Damage-Related Biomarkers PHASE4COMPLETED
Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin PHASE2/PHASE3UNKNOWN
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease PHASE2COMPLETED
Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection PHASE1/PHASE2COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
Sodium Citrate in Smell Retraining for People With Post-COVID-19 Olfactory Dysfunction PHASE2ACTIVE_NOT_RECRUITING
Biologic Correlative Taxotere/AC PHASE2COMPLETED
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm PHASE1RECRUITING
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas PHASE1COMPLETED
Can E-cadherin Found in Tissue/Blood be Valuable in Identifying & Monitoring Patients With Post-proton Pump Inhibitor (PPI)-Responsive Heartburn PHASE1COMPLETED
Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors PHASE1COMPLETED
Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D) EARLY_PHASE1COMPLETED
Assessing Bone Calcium Content in Children With Kidney Disease Treated With Two Different Medicines nanUNKNOWN
Characteristics of Patients With Philadelphia Negative Myeloproliferative Neoplasms at Assiut University Hospital nanUNKNOWN
Carnosine Supplementation on Quantity/Quality of Oral Salivae. nanUNKNOWN
Ruxolitinib in Patients With Myelofibrosis nanUNKNOWN
Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer nanCOMPLETED
IMI PROTECT (Work Package 2): Calcium Channel Blockers and Cancer nanCOMPLETED
Predicting Pancreatic Necrosis Using mitDNA nanUNKNOWN
High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions nanCOMPLETED
Mitochondrial Assessment in Critical Ill Patients in Intensive Care nanNOT_YET_RECRUITING
Dynamics of Muscle Mitochondria in Type 2 Diabetes Exercise nanCOMPLETED
MRI Biomarkers in ALS nanCOMPLETED
Relationship of Gestational Age and Urine Concentration of S100B in Preterm and Term Infants in the First Week of Life nanCOMPLETED
Mucin in Sputum of CF During Pulmonary Exacerbation nanUNKNOWN
Dysfunctions of Human Muscle Stem Cells in Sepsis nanCOMPLETED
Role of Piwi-protein Interacting RNA, miRNA-194 and Amino Acids in Patients With Prostate Cancer nanUNKNOWN
Evaluating Changes in Skeletal Muscle Proteins Following Resistance Exercise and Single-Leg Disuse nanCOMPLETED
Skeletal Muscle Regeneration in Survivors of Critical Illness: How to Prevent Satellite Cell Failure? nanRECRUITING
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CALU binder may also engage these)

ProteinNameSimilarity
Q6XLQ7 1.000 Q6XLQ7 →
Q5RDD8 1.000 Q5RDD8 →
O35887 1.000 O35887 →
Q4U471 0.996 Q4U471 →
Q3T0K1 0.991 Q3T0K1 →
B5X4E0 0.975 B5X4E0 →
O35783 0.972 O35783 →
Q28BT4 0.971 Q28BT4 →
Q05186 0.967 Q05186 →
Q6IP82 0.965 Q6IP82 →
Q62703 0.963 Q62703 →
Q8BP92 0.962 Q8BP92 →
Q7SXV9 0.960 Q7SXV9 →
RCN1 Reticulocalbin-1 0.960 landscape →
Q14257 0.953 Q14257 →
B1H2N3 0.941 B1H2N3 →
B5X186 0.939 B5X186 →
Q8VCX5 0.935 Q8VCX5 →
Q9BPX6 0.935 Q9BPX6 →
Q6IQP3 0.935 Q6IQP3 →
Q6P6Q9 0.934 Q6P6Q9 →
Q8NI22 0.933 Q8NI22 →
Q0IIL1 0.930 Q0IIL1 →
Q5R8Z6 0.930 Q5R8Z6 →
Q8K5B3 0.930 Q8K5B3 →
O93434 0.930 O93434 →
Q4R518 0.928 Q4R518 →
Q5U4X8 0.925 Q5U4X8 →
Q8K5B2 0.922 Q8K5B2 →
Q3UHN9 0.919 Q3UHN9 →